Answers are grounded in this paper and cite their sources.
The above observations suggest that TGF-β2 and hepcidin form a self-sustained feed-forward loop through iron-catalyzed ROS. This loop is partially disrupted by a hepcidin antagonist and an anti-oxidant, implicating iron and ROS in TGF-β2-mediated POAG. We propose that modification of currently available hepcidin antagonists for ocular use may prove beneficial for the therapeutic management of TGF-β2-associated POAG.
No takes yet. Share an insight, caveat, or question.
Ashok et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: